All posts by medical

What Does It Take To See Gentrification Before It Happens? – NPR

Gentrification brings with it new restaurants, businesses and housing but often pushes out longtime residents. Jay Lazarin/Getty Images hide caption

Gentrification brings with it new restaurants, businesses and housing but often pushes out longtime residents.

Gentrification of neighborhoods can wreak havoc for those most vulnerable to change.

Sure, access to services and amenities rise in a gentrifying neighborhood. That is a good thing. But those amenities won't do you much good if you're forced to move because of skyrocketing housing costs.

That is why neighborhood and housing advocacy groups have spent decades searching for ways to protect longtime residents from the negative effects of gentrification.

But how can you tell if a neighborhood is gentrifying? Is it the art gallery that appears next to the bodegas? Is it the hipster coffee shop opening up where the old deli used to be? Maybe it's the expensive new condos rising up across from the older row houses? The problem with any of these obvious indicators is that by the time they appear, it may already be too late. The tide of living expenses in a given neighborhood may already be rising so fast that there is little that local groups, city planners or outside agencies can do. If you're poor or working class, it's just time to leave.

But what if there were a way to see gentrification long before the coffee shops, condos and Whole Foods appear? What if city planners and neighborhoods had an early warning system that could sniff out the changes just as they begin? In that way, cities might prepare for the coming changes securing a diverse range of housing options before land and rent prices shoot through the roof.

A neighborhood early warning system like this has been a dream for city planners for decades. The first versions of it stretch back as far as the 1980s. Now, though, with the rise of big data, this dream has taken a giant step forward toward becoming a reality. As with all things big data, however, taking that step comes with both considerable promise and peril.

Big data is a shorthand term for the insane amounts of information being generated by human beings in our digital world. From cellphones to credit card transactions to social media, we are all leaving digital contrails of almost all of our activity in the world. Learning how to harvest and analyze these digital traces en masse holds the promise of allowing data scientists to see how societies operate at a resolution that was simply impossible before. And seeing hidden patterns in gentrification may be exactly the kind of task big data and data science are best at.

So what does it take to see gentrification before it happens? The most obvious indicator is housing prices. Cities have always done a pretty good job of keeping track of property sales. That is why those records have, for many decades, been the primary data set for studies of neighborhood change. But big data has already swept through the housing price field, as apps like Zillow and Trulia allow anyone access to real estate information going back years. Using a data science technique called machine learning, computers can analyze patterns in these real estate records and extract future trends allowing companies to try to predict what your house will be worth next year.

But even if it works, this kind of "predictive analytics" for housing prices is too blunt an instrument to predict which neighborhoods might gentrify. To really develop an early warning system, data scientists need to go deeper into human behavior. Going deeper, however, means getting new kinds of data.

Evictions of both people and businesses might be one of the best representations of how gentrification negatively affects a neighborhood. But unlike real estate transactions, most cities do a terrible job of keeping track of who, where and why evictions are initiated. Getting that data used to mean a trip to city hall to dig through the musty records department. Because of this, evictions remain invisible to data scientists in their search for gentrification indicators.

A different kind of problem is faced by urban scientists who want to see who exactly is moving into, and out of, the neighborhoods. How does the economic and racial profile of a neighborhood change when gentrification occurs? Data from the U.S. census contains a wealth of information relevant to this question but it comes just once a decade. That is too slow to catch the details of a changing neighborhood. Social scientists also have what is called the American Community Survey, which is done every year. But it's a fraction of the size of the census and, like a bad cellphone camera, it doesn't have the resolution scientists need to see the spatial details of how neighborhoods change.

The difficulties in these tools limited earlier heroic attempts at building a neighborhood early warning system. But with big data, the situation has radically changed. Rather than asking a handful of people a few direct questions about their lives, these days we're all leaving volumes of answers about ourselves in the data we generate just, for example, by using our phones.

Consider a study from October 2015 that used Twitter to look at how residents of different neighborhoods moved around the city of Louisville, Ky. For generations, Louisville residents have seen Ninth Street as the boundary of the poorer African-American neighborhood to the west and wealthier white neighborhood to the east. But by carefully tracking tweets that were geotagged, meaning they contained location information, researchers could study mobility patterns of residents in the different neighborhoods. In particular, they found that Twitter users from the western neighborhoods were far more likely to be found in different regions of the city than residents of the eastern neighborhoods. In this way, the researchers found that the traditional boundaries of the neighborhoods could be redrawn based on the way people actually behaved rather than just "common wisdom."

The Louisville research highlights how studies of what is called "human mobility" can provide ground-truth insights into how neighborhoods function for the people who use them. In the future, perhaps, it will be possible to identify gentrifying neighborhoods by looking for unexpected patterns in how people travel into and out them on a daily basis. Studies of the mixing of ethic groups in Estonia tracked changes in neighborhood composition between the daytime and nighttime hours as well as weekday vs. weekend. By analyzing these patterns over months or years, it may be possible to see the "signal" of gentrification appear as people who normally would not be visiting a neighborhood begin making more frequent appearances.

With an early warning system in place, neighborhood advocates would have the opportunity to implement policies ranging from reserving affordable housing units to educating residents of their renting rights to helping small businesses negotiate long-term lease extensions.

And given that gentrification represents a small problem compared with existing urban poverty, early warning systems could also be applied to the other direction of neighborhood change. Using big data alongside traditional social science methods, it may be possible to identify neighborhoods at risk of decline. In this way, predictive analytics would let residents and city officials take steps to keep these at-risk neighborhoods healthy through early intervention in the availability of services or policing.

The methods of big data might even allow neighborhood equality to be crowdsourced. A recent study using data from cellphones and credit card transactions tracked shopping trips across a range of rich and poor neighborhoods in Spain. By rewiring just 5 percent of those shopping trips to more economically challenged neighborhoods, the researchers found income disparity could be significantly flattened. That means that by changing the destination of just 5 out of 100 of our shopping trips, we might all be a source for positive change.

But, as is becoming clear with everything to do with big data, while advances hold great promise for dealing with neighborhood change, they also hold significant peril. The great hope of urban advocates is to democratize data and its analysis tools, allowing residents and other stakeholders to see more clearly how a neighborhood is changing. But knowledge of those changes might act in a way that accelerates them. Seeing gentrification early may spur more development more quickly. Seeing neighborhoods decline early may provide more disincentive for investment.

As the first wave of optimism for big data passes, both researchers and users have become more realistic about its possibilities. But with eyes wide open, we may be at the beginning of seeing human communities in an entirely new way. From this new vantage point we will, hopefully, have new tools to ensure their health and well-being, even in the midst of change.

(Special thanks to Solomon Greene of the Urban Research Institute for his help with this post.)

Adam Frank is a co-founder of the 13.7 blog, an astrophysics professor at the University of Rochester, a book author and a self-described "evangelist of science." You can keep up with more of what Adam is thinking on Facebook and Twitter: @adamfrank4

Read more from the original source:
What Does It Take To See Gentrification Before It Happens? - NPR

Anatomy Lab LIVE returns to Cardiff and this is when you can see it – WalesOnline

A live show where the audience participate in a human dissection after tucking into a slap up meal is coming to Cardiff .

After selling out venues across the UK earlier this year, Anatomy Lab LIVE returns but even bigger, or even more disgusting, than ever before.

The show is a touring hands-on post-mortem suite, which serves a sumptuous two-course dinner to guests before the gory procedure begins.

Guests will will be given mortuary wear including protective surgical hats, masks and aprons as well as scalpels, scissors, forceps and bone saws before attempting a post mortem dissection, lead by the show's experts.

Those with a tough stomach will also be wined and dined, shortly before Samuel Piri and Scarlett Mellor will begin the dissection of VIVIT the world's only semi-synthetic human cadaver.

There will be an in-depth observation of various disease states before the mortuary technicians bring samples out into the audience for a closer look.

It will take place at The Village Hotel in Cardiff.

On Saturday, February 24.

The inner anatomy of the head including the cranial cavity, brain, spinal cord and the jaw.

The trachea, lungs, heart and diaphragm.

The digestive tract, including the stomach, liver, gall bladder, small intestine, large intestine, rectum and anus.

All of VIVITs organs come from pigs because of their anatomical similarities with humans.

Audiences will have the chance to put their questions to the anatomist and to leading medics who will be him on stage. Various samples will then be placed around the room in small pods where people will don surgical wear to dissect the samples revealing their internal structures.

You will get to:

There'll be an option of chicken or vegetarian.

Yes the event is for 16+.

Ticket prices start from 70 per person online from Eventbrite or you can buy a group ticket for six people for 430.

The cost includes a two-course sit down meal before the dissection starts. Vegetarian options can be requested in advance.

You can contact the box office on 01675 479818 Monday to Saturday 9am-8pm and Sundays from 10am-5pm.

Here is the original post:
Anatomy Lab LIVE returns to Cardiff and this is when you can see it - WalesOnline

Grey’s Anatomy: Catherine Almost Sidelined Bailey Over Karev’s Assault – TV Guide

Now PlayingGrey's Anatomy Deleted Scene: Catherine Almost Side-Lined Bailey Over Karev

It turns out Karev's (Justin Chambers) violent takedown of DeLuca (Giacomo Gioniotti) at the end of Season 12 had even more ramifications than fans knew.

TV Guide has obtained a deleted scene from the Grey's Anatomy Season 13 DVD set that reveals the fallout from Karev's arrest for DeLuca's beatdown almost got Bailey (Chandra Wilson) sidelined as Chief of Surgery. In the wake of Karev leaving the hospital in handcuffs, Catherine (Debbie Allen) came in guns blazing and questioned if Bailey was ready to do what needed to be done if their pediatric resident was being arrested for aggravated assault.

Bailey wasn't ready to fire Karev before finding out the full story, but she wasn't ready to let Catherine bring in someone else either -- thank God. We all know how it turned out later in the season when Catherine steamrolled Bailey into bringing someone else into the hospital (Hello, Minnick!). Bailey never did fire Karev, and that ended up working out for everyone, except maybe DeLuca.

Grey's Anatomy Mega Buzz: Are Maggie and Jackson Actually a Thing?

Luckily, Bailey is still sitting pretty as Chief of Surgery and everything seems to have worked out -- for now.

Grey's Anatomy returns with a two-hour premiere on Thursday, Sept. 28 at 8/7c on ABC.

Visit link:
Grey's Anatomy: Catherine Almost Sidelined Bailey Over Karev's Assault - TV Guide

M v F & SM (Human Fertilisation and Embryology Act 2008) [2017] EWHC 2176 (Fam) (23 August 2017) – Family Law Week

Home > Judgments

Case summary coming soon

Neutral Citation Number: [2017] EWHC 2176 (Fam)Case No: LE17P00251IN THE HIGH COURT OF JUSTICEFAMILY DIVISIONBirmingham Civil Justice CentreB4 6DS

Date: 23/08/2017

Before :

MR. JUSTICE KEEHAN- - - - - - - - - - - - - - - - - - - - -Between :

M Applicant- and - F 1st RespondentSM2nd Respondent- and -A (BY HIS GUARDIAN)3rd Respondent

- - - - - - - - - - - - - - - - - - - - -- - - - - - - - - - - - - - - - - - - - -

Andrew Powell (instructed by JMW Solicitors LLP) for the The ApplicantThe 1st Respondent did not attend and was not representedKatherine Duncan (instructed by Mills & Reeve) for the The 2nd RespondentMartin Kingerley (instructed by CAFCASS) for the The 3rd Respondent

Hearing dates: 4th July 2017- - - - - - - - - - - - - - - - - - - - -Judgment Approved

MR. JUSTICE KEEHAN

This judgment was delivered in private. The judge has given leave for this version of the judgment to be published on condition that (irrespective of what is contained in the judgment) in any published version of the judgment the anonymity of the children and members of their family must be strictly preserved. All persons, including representatives of the media, must ensure that this condition is strictly complied with. Failure to do so will be a contempt of court.

Mr. Justice Keehan : INTRODUCTION1.In early 2017 A was born. His biological parents are the applicant, M and the first respondent, F. His legal parents are, however, the second respondent, SM and F, although he does not have parental responsibility for the child.

2.A was born as a result of a gestational surrogacy arrangement between the applicant and the first respondent. Their gametes were used to create an embryo that was then implanted in the second respondent on 29 May 2016. Immediately upon his birth the second respondent surrendered care of A to the applicant.

3.During the course of the second respondent's pregnancy, the relationship between the applicant and the first respondent ended. Unless the law is changed to permit applications for parental orders by a single applicant, the applicant will not be entitled to obtain this transformative order to become A's legal as well as biological parent.

4.In order to provide stability for the child and some legal status for the applicant, the court made A a Ward of Court on 28 February 2017, granted care and control of him to the applicant and prohibited the first respondent from removing the child from her care. The order contained the following recital:

"And Upon the court reading the letter of the first respondent dated 24 February 2017, in which the first respondent indicates that he has taken the decision not to be involved in these proceedings or the child's upbringing."

5.The matter was then listed before me for directions on 12 April 2017 and further on 4 July when the parties invited me to give this judgment.

BACKGROUND6.For the purposes of this judgment I can set out the background to this case very briefly. The applicant and the first respondent began a relationship in 2011. They wished to have children but for medical reasons the applicant was unable to conceive. A cycle of IVF treatment, funded by the NHS, was unsuccessful and the couple could not afford to pay privately for further IVF treatment.

7.The applicant and first respondent then considered surrogacy and were delighted when the friend of a family member volunteered to be a surrogate for them.

8.In 2015 they engaged a fertility clinic to assist them. Once all the necessary formalities had been completed an embryo was created using the applicant's and first respondent's gametes. The second respondent was implanted with the embryo on 29 May 2016.

9.During the course of the pregnancy the relationship between the applicant and the first respondent deteriorated and finally they separated before A's birth. I do not propose to include in this judgment how or why they separated.

10.Since A's birth the second respondent has surrendered his care to the applicant. She has no wish to be involved in the upbringing of A and would be content for a parental order to be made in favour of the applicant if that route was in law available to her. She would support A remaining in the care of the applicant and any orders which would terminate her parental responsibility for him or prohibit her from exercising her parental responsibility.

11.The first respondent has played no role whatsoever in A's life. He has not seen him. As noted above he does not wish to be involved in his child's upbringing. He is, of course, the only biological and legal parent that A has, as matters stand.

12.The applicant is in the process of issuing an application for a parental order within six months of A's birth. She recognises that the application will be stayed pending a change in the law following on from the President's declaration of incompatibility in Re Z (A Child) (No.2): see below.

THE LAW13.A parental order made pursuant to s.54 of the Human Fertilisation and Embryology Act 2008 ('the 2008 Act') provides for the child to be treated in law as the child of the applicants. The order may be made if the conditions set out in s.54 of the 2008 Act are satisfied.

14.The act provides that:

(1) On an application made by two people ("the applicants"), the court may make an order providing for a child to be treated in law as the child of the applicants if

(a) the child has been carried by a woman who is not one of the applicants, as a result of the placing in her of an embryo or sperm and eggs or her artificial insemination,

(b) the gametes of at least one of the applicants were used to bring about the creation of the embryo, and

(c) the conditions in subsections (2) to (8) are satisfied.

(2)The applicants must be

(a) husband and wife,

(b) civil partners of each other, or

(c) two persons who are living as partners in an enduring family relationship and are not within prohibited degrees of relationship in relation to each other.

(3) Except in a case falling within subsection (11), the applicants must apply for the order during the period of 6 months beginning with the day on which the child is born.

(4) At the time of the application and the making of the order

(a) the child's home must be with the applicants, and

(b) either or both of the applicants must be domiciled in the United Kingdom or in the Channel Islands or the Isle of Man.

(5) At the time of the making of the order both the applicants must have attained the age of 18.

(6) The court must be satisfied that both

(a) the woman who carried the child, and

(b) any other person who is a parent of the child but is not one of the applicants (including any man who is the father by virtue of section 35 or 36 or any woman who is a parent by virtue of section 42 or 43),have freely, and with full understanding of what is involved, agreed unconditionally to the making of the order.

(7) Subsection (6) does not require the agreement of a person who cannot be found or is incapable of giving agreement; and the agreement of the woman who carried the child is ineffective for the purpose of that subsection if given by her less than six weeks after the child's birth.

(8) The court must be satisfied that no money or other benefit (other than for expenses reasonably incurred) has been given or received by either of the applicants for or in consideration of

(a) the making of the order,

(b) any agreement required by subsection (6),

(c) the handing over of the child to the applicants, or

(d) the making of arrangements with a view to the making of the order,unless authorised by the court.

15.For the purposes of this judgment the relevant statutory provisions of s.54 are:

i)s.54(1) which requires the application to be made by two people;

ii)s.54(2) which requires the applicants to be either husband and wife, or civil partners or persons who are living as partners in an enduring family relationship; and

iii)s.54(4)(a) which requires that the child's home must be with the applicants.

16.In Re Z (A Child: Human Fertilisation and Embryology Act: Parental Order) [2015] EWFC 73 the President declined to read down the provisions of s.54 of the 2008 Act to permit an application for a parental order by a single applicant.

17.In Re Z (A Child) (No.2) [2016] EWHC 1191 (Fam), [2016] 2 FLR 327, the President made a declaration of incompatibility in respect of s.54 in the following terms at paragraph 17 "sections 54(1) and (2) of the Human Fertilisation and Embryology Act 2008 are incompatible with the rights of the Applicant and the Second Respondent under Article 14 ECHR taken in conjunction with Article 8 insofar as they prevent the Applicant form obtaining a parental order on the sole ground of his status as a single person as opposed to being part of a couple."

18.The transformative legal effect of a parental order cannot be overstated. The only alternatives are:

i)An adoption order, but, on the facts, it would be inappropriate for the biological mother to become in law the adoptive mother of her own child in order to gain the status of being the child's legal parent; or

ii)Making the child a ward of court, granting and control of the child to the applicant and making such ancillary orders as to minimise the number of occasions the applicant would have to apply to the court: see Re Z (A Child) (No. 2) above and the judgment of the President at paragraph 7. But these collections of orders do not make the applicant the legal parent of the child.

19.In Re X (A Child) (Surrogacy: Time Limit) [2014] EWHC 3135 (Fam) the President said at paragraph 54

54. Section 54 goes to the most fundamental aspects of status and, transcending even status, to the very identity of the child as a human being: who he is and who his parents are. It is central to his being, whether as an individual or as a member of his family. As Ms Isaacs correctly puts it, this case is fundamentally about Xs identity and his relationship with the commissioning parents. Fundamental as these matters must be to commissioning parents they are, if anything, even more fundamental to the child. A parental order has, to adopt Theis J's powerful expression, a transformative effect, not just in its effect on the child's legal relationships with the surrogate and commissioning parents but also, to adopt the guardian's words in the present case, in relation to the practical and psychological realities of X's identity. A parental order, like an adoption order, has an effect extending far beyond the merely legal. It has the most profound personal, emotional, psychological, social and, it may be in some cases, cultural and religious, consequences. It creates what Thorpe LJ in Re J (Adoption: Non-Patrial) [1998] INLR 424, 429, referred to as "the psychological relationship of parent and child with all its far-reaching manifestations and consequences." Moreover, these consequences are lifelong and, for all practical purposes, irreversible: see G v G (Parental Order: Revocation) [2012] EWHC 1979 (Fam), [2013] 1 FLR 286, to which I have already referred. And the court considering an application for a parental order is required to treat the child's welfare throughout his life as paramount: see in In re L (A Child) (Parental Order: Foreign Surrogacy) [2010] EWHC 3146 (Fam), [2011] Fam 106, [2011] 1 FLR 1143. X was born in December 2011, so his expectation of life must extend well beyond the next 75 years. Parliament has therefore required the judge considering an application for a parental order to look into a distant future.

20.I respectfully agree.

DISCUSSION21.Following the President's declaration of incompatibility in Re Z (A Child) (No. 2) above, the Government is actively considering the terms of a remedial order to address the incompatibility identified in that case: see paragraph 17 above.

22.The applicant earnestly hopes that that the terms of the remedial order will be such that she will be able to apply for a parental order. This 'transformative' order would enable her to be a legal parent of A.

23.In the meantime I am satisfied that it is in A's welfare best interests for the court to approve the continuation of the wardship and the grant of care and control in respect of him to the applicant.

24.In giving this judgment I have well in mind the words of the President in Re Z (A child) (No. 2) where at paragraph 26-28 and 30 he said

26. They submit that the use of the remedial power under section 10 is "appropriate and necessary in this case because it would ensure that [the father] could apply for a parental order with minimum delay, and would prevent Z remaining in a legally vulnerable position for any longer than is absolutely necessary."

27. Going even further, they invite me to "pass comment (by way of obiter dicta) about the merits of Parliamentary review of the scheme of section 54" and to "express any view as to the desirability or necessity for future reform as may be considered appropriate.

28. I absolutely decline to do any of this.29. On behalf of the Secretary of State, Miss Broadfoot and Miss Gartland understandably counsel great caution. First, they point out correctly as it seems to me that there are various different ways in which the discriminatory effect of the present legislation could be cured. Secondly, they observe that this is an area of social policy in relation to a matter surrogacy which is controversial. Thirdly, they submit, and I agree, that it is constitutionally a matter for the legislature to determine its response. Fourthly, they submit, and again I agree, that it is entirely a matter for the government to decide whether or not to utilise the Ministerial power under section 10. It is important to note the language of section 10(2). It is a matter for "a Minister", therefore not for a judge, to "consider" whether there are "compelling reasons." Moreover, as they point out, the court can be in no position to know whether such compelling reasons exist, as this may depend upon a number of factors of which the court can have no knowledge or in respect of which it may be lacking in relevant expertise. Fifthly, and finally, they caution that any observations I might be tempted to make may have unintended implications and unforeseen consequences."

25.Once again, I respectfully agree.

Read the original here:
M v F & SM (Human Fertilisation and Embryology Act 2008) [2017] EWHC 2176 (Fam) (23 August 2017) - Family Law Week

Shire launches new ADHD drug Mydayis as it weighs a neuroscience exit – FiercePharma

Despite earlier this month announcing its considering a sale of ADHD offerings, Shire has launched its latest Adderall formulation in the U.S. The company on Monday started selling Mydayis at a price of $271 per month before rebates and discounts, hoping to achieve $500 million in annual sales.

Shire had been marketing its new medication on a limited basis, but nowthe rollout has begun in earnest. It includes a copay offer for commercially insured patients, according to a release. In an interview, Shires head of global communications for ophthalmics and neuroscience, Clotilde Houz, said the launch provides the ADHD community a new treatment option.

We know that not all patients respond to medications in the same way, Houz said. We really want to support physicians and patients who might want different treatment options.

Mydayis won approval back in June based on 16 clinical trials incorporating more than 1,600 participants. The once-daily medication helped patients scores on a validated attention test, with effects starting within 2 to 4 hours and lasting up to 16 hours, according to the drugmaker. Mydayis is approved for ADHD patients 13 and older.

RELATED: Can Shire's new Mydayis, its latest Adderall iteration, really nab $500M in sales?

Weve been working since the FDA approval to properly train our salesforce and make sure that they have all of the information needed to talk to the physicians, Houz said, without disclosing how many representatives are supporting the launch.

She added that the 16-hour effect for Mydayis may be a benefit physicians seek out for treating their patients.

Sales expectations are mixed on the new drug, with the companys own thoughts coming in ahead of Wall Streets. At the time of approval, consensus analyst projections were for $288 million in sales by 2020, significantly short of Shires aspirations of $500 million for that year.

Shire priced its drug competitively and in consideration of the innovation and value it delivers, according to a company statement. Payer negotiations are ongoing, Houz said, adding that the company looks forward to sharing more news on that in the future.

To reach its $500 million sales ambition for 2020, Shire has said itll lean on its leadership position and experience in ADHD. Since the FDA approval for Mydayis, however, the Irish drugmaker has disclosed it may be looking to get out of neuroscience altogether.

RELATED: Shire hints at ADHD spinoff, but could someone step in and buy the neuro franchise?

In its second-quarter earnings announcement, the drugmaker disclosed its assessing strategic options for the group, potentially including an independent public listing. During the quarter, Vyvanse sales stayed flat versus the prior year at $518 million, while Adderall XR slipped 30% to $71 million.

Mydayis FDA approval followed a green light at the agency for Neos Therapeutics Cotempla, an extended-release ADHD drug that melts in the mouth. More than 10 million adults have ADHD in the U.S., according to Shire.

The company will continue its disease awareness campaign, but because Mydayis is a class 2 stimulant, Shire needs to await FDA guidance for DTC advertising, Houz said.

The rest is here:
Shire launches new ADHD drug Mydayis as it weighs a neuroscience exit - FiercePharma

Scientist expects biomed research to remain focused on antibodies – Focus Taiwan News Channel

Taipei, Aug. 28 (CNA) Antibody and small molecule drugs and big data applications will remain at the center of biomedical research in the future, according to Andrew Wang (), president-elect of the International Union of Biochemistry and Molecular Biology (IUBMB).

Wang was speaking on the future development of biomedical technology in a recent interview with CNA, in which he encouraged local scientists to find the right directions if they decide to devote themselves to antibody drug research and development.

Biomedicine is an emerging sector that has attracted many scientists around the world, said the chemist, who serves as the distinguished visiting chair of the Institute of Biological Chemistry at Academia Sinica, Taiwan's top academic research institution.

Wang also encouraged researchers to seek new techniques, citing the example of French scientist Emmanuelle Charpentier and Americans Jennifer A. Doudna and Feng Zhang (), the trio who shared the 2016 Tang Prize for biopharmaceutical science.

They were honored for the development of the CRISPR/Cas9, a genome editing tool that enables geneticists and medical researchers to edit DNA, using a technique that has the potential for a wide range of applications, according to the Tang Prize Foundation.

Wang praised the CRISPR/Cas9 as a big breakthrough, and he expected it to significantly affect future research, which he said could even reach the aspect of biological transformation.

"In the future, cell therapies will become very important," Wang said.

In addition to antibody and small molecule drug research, changes in medical treatment methods are a direction that local scientists can also turn to, Wang said, noting that the results of big data analysis related to health insurance practices can be applied in the precision medicine sector.

The Tang Prize awards were established by Taiwanese entrepreneur Samuel Yin () in 2012 to honor people who have made significant contributions in the fields of sustainable development, biopharmaceutical science, sinology and rule of law. They are dubbed as the "Asian Nobel Prize."

The IUBMB is an international non-governmental organization concerned with biochemistry and molecular biology. Founded in 1955, it unites biochemists and molecular biologists in 75 countries that belong to the union as an adhering body or associate adhering body represented by a biochemical society, a national research council or an academy of sciences.

(By Yu Hsiao-han and Elizabeth Hsu)Enditem/sc

Read more:
Scientist expects biomed research to remain focused on antibodies - Focus Taiwan News Channel

Cancer breakthrough: Scientists discovery new process which triggers death of cancer cells – Express.co.uk

GETTY

The team of British researchers believe the groundbreaking method could shrink tumours and be more effective than any other existing treatments - such as chemotherapy.

The new process which kills off cancer cells has been called Caspase Independent Cell Death (CICD) and in trials led to the complete eradication of tumours in experimental models.

Scientists now believe the groundbreaking new research, published in Nature Cell Biology, could revolutionise the way cancer is tackled.

Lead author Dr Stephen Tait, from the University of Glasgow, explained: We were interested in identifying an alternative way to kill cancer cells. And weve identified a process called Caspase Independent Cell Death that appears, really excitingly, to be more effective (than other current methods).

Currently, most anti-cancer therapies - chemotherapy, radiation and immunotherapy - work by killing cancer cells through a process called apoptosis, which activates proteins called caspases, leading to cell death.

We were interested in identifying an alternative way to kill cancer cells

Lead author Dr Stephen Tait

But in apoptosis, therapies often fail to kill all the cancer cells, leading to disease recurrence, and can also have unwanted side effects that may even promote cancer.

The scientists at the University of Glasgow wanted to develop a way to improve therapy that induces cancer cell killing while also mitigating unwanted toxicity.

Announcing the successful new process, Dr Tait, also of the Cancer Research UK Beatson Institute, Institute of Cancer Sciences, said: Our research found that triggering Caspase-Independent Cell Death (CICD), but not apoptosis, often led to complete tumour regression.

Especially under conditions of partial therapeutic response, as our experiments mimic, our data suggests that triggering tumour-specific CICD, rather than apoptosis, may be a more effective way to treat cancer.

Unlike apoptosis, which is a silent form of cell death, when cancer cells die through CICD, they alert the immune system through the release of inflammatory proteins.

The immune system can then attack the remaining tumour cells that evaded initial therapy-induced death.

The researchers used lab-grown colorectal cancer cells to show the advantage of killing cancer cells via CICD, however, these benefits may be applicable to a wide-range of cancer types.

Getty Images

1 of 11

How to prevent skin cancer

Dr Tait added: In essence, this mechanism has the potential to dramatically improve the effectiveness of anticancer therapy and reduce unwanted toxicity.

"Taking into consideration our findings, we propose that engaging CICD as a means of anti-cancer therapy warrants further investigation.

And he explained why it could be more effective than existing traditional treatments such as chemotherapy or radiotherapy.

He said: What we found in essence is the cells that undergo Caspase Independent Cell Death, they stimulate an immune response against the rest of the rumour.

In effect, you dont necessarily need to kill all the tumour cells with therapy because weve now elicited an immune response that then clears out the remaining tumour - in doing so eradicating the cancer.

GETTY

Latest figures show that half of all Britons born after 1960 will be diagnosed with some form of cancer during their lifetime.

Experts say four in 10 cancer cases are linked to lifestyle factors.

Smoking remains the largest single preventable cause.

More than half of cancer deaths in the UK are of people aged 75 years and over.

Last night, cancer research bodies in the UK gave the new research a warm welcome.

GETTY

Dr Justine Alford, Cancer Research UKs senior science information officer, said: Although many cancer treatments work by triggering apoptosis, that method sometimes fails to finish the job and instead may lead to the tumour becoming harder to treat.

And she added: This new research suggests there could be a better way to kill cancer cells which, as an added bonus, also activates the immune system.

Now scientists need to investigate this idea further and, if further studies confirm it is effective, develop ways to trigger this particular route of cell death in humans.

The new paper is published in Nature Cell Biology.

The paper was majority funded by Cancer Research UK.

Read the original post:
Cancer breakthrough: Scientists discovery new process which triggers death of cancer cells - Express.co.uk

FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments – NPR

Adult stem cells can be extracted from human fat. Patrick T. Fallon /The Washington Post/Getty Images hide caption

Adult stem cells can be extracted from human fat.

The Food and Drug Administration is cracking down on "unscrupulous" clinics selling unproven and potentially dangerous treatments involving stem cells.

Hundreds of clinics around the country have started selling stem cell therapies that supposedly use stem cells but have not been approved as safe and effective by the FDA, according to the agency.

"There are a small number of unscrupulous actors who have seized on the clinical promise of regenerative medicine, while exploiting the uncertainty, in order to make deceptive, and sometimes corrupt assurances to patients based on unproven and, in some cases, dangerously dubious products," FDA Commissioner Scott Gottlieb said in a statement Monday.

The FDA has taken action against clinics in California and Florida.

The agency sent a warning letter to the US Stem Cell Clinic of Sunrise, Fla., and its chief scientific officer, Kristin Comella, for "marketing stem cell products without FDA approval and significant deviations from current good manufacturing practice requirements."

The clinic is one of many around the country that claim to use stem cells derived from a person's own fat to treat a variety of conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lung and heart diseases, the FDA says.

The Florida clinic had been previously linked to several cases of blindness caused by attempts to use fat stem cells to treat macular degeneration.

The FDA also said it has taken "decisive action" to "prevent the use of a potentially dangerous and unproven treatment" offered by StemImmune Inc. of San Diego, Calif., and administered to patients at California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, Calif.

As part of that action, the U.S. Marshals Service seized five vials of live vaccinia virus vaccine that is supposed to be reserved for people at high risk for smallpox but was being used as part of a stem-cell treatment for cancer, according to the FDA. "The unproven and potentially dangerous treatment was being injected intravenously and directly into patients' tumors," according to an FDA statement.

Smallpox essentially has been eradicated from the planet, but samples are kept in reserve in the U.S. and Russia, and vaccines are kept on hand as a result.

But Elliot Lander, medical director of the California Stem Cell Treatment Centers, denounced the FDA's actions in an interview with Shots.

"I think it's egregious," Lander says. "I think they made a mistake. I'm really baffled by this."

While his clinics do charge some patients for treatments that use stem cells derived from fat, Lander says, none of the cancer patients were charged and the treatments were administered as part of a carefully designed research study.

"Nobody was charged a single penny," Lander says. "We're just trying to move the field forward."

In a written statement, U.S. Stem Cell also defended its activities.

"The safety and health of our patients are our number one priority and the strict standards that we have in place follow the laws of the Food and Drug Administration," according to the statement.

"We have helped thousands of patients harness their own healing potential," the statement says. "It would be a mistake to limit these therapies from patients who need them when we are adhering to top industry standards."

But stem-cell researchers praised the FDA's actions.

"This is spectacular," says George Daley, dean of the Harvard Medical School and a leading stem-cell researcher. "This is the right thing to do."

Daley praised the FDA's promise to provide clear guidance soon for vetting legitimate stem-cell therapies while cracking down on "snake-oil salesmen" marketing unproven treatments.

Stem-cell research is "a major revolution in medicine. It's bound to ultimately deliver cures," Daley says. "But it's so early in the field," he adds. "Unfortunately, there are unscrupulous practitioners and clinics that are marketing therapies to patients, often at great expense, that haven't been proven to work and may be unsafe."

Others agreed.

"I see this is a major, positive step by the FDA," says Paul Knoepfler, a professor of cell biology at the University of of California, Davis, who has documented the proliferation of stem-cell clinics.

"I'm hoping that this signals a historic shift by the FDA to tackle the big problem of stem-cell clinics selling unapproved and sometimes dangerous stem cell "treatments" that may not be real treatments," Knoepfler says.

Go here to read the rest:
FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - NPR

Repetitive elements shape embryonic chromatin landscape – Phys.Org

Murine 2-cell stage embryo: L1 transcripts are visualized in white, DNA is shown in blue. Credit: Helmholtz Zentrum Mnchen

Retrotransposons are repetitive elements that form almost half of the mammalian genome. Even though they are so common, they have previously been considered to be fairly insignificant. Together with colleagues from the USA, scientists from the Helmholtz Zentrum Mnchen have now shown in Nature Genetics that retrotransposons play an important role in embryonic development.

The researchers specifically investigated the role of so-called LINE1 (L1) elements, the most abundant retrotransposon family in mammals. "We already knew L1 elements to be highly expressed in early embryogenesis and so we wanted to know if this transcription is important in the events taking place in the early embryo" says Prof. Dr. Maria Elena Torres-Padilla who headed the study. She is director of the Institute of Epigenetics and Stem Cells (IES) at Helmholtz Zentrum Mnchen and professor of Stem Cell Biology at the Ludwig-Maximilians-Universitt Mnchen (LMU).

"Critical for the development of the embryo"

Examining the expression of L1 in an experimental model, the researchers observed a peak when the embryo consists of only 2 cells, followed by a decrease in expression by the time the embryo attaches to womb of the mother. These stages are crucial for a successful pregnancy. To understand the importance of L1 elements they used artificially designed transcription factors (TALE, for transcription activator-like effector) to prevent or promote L1 expression in embryos. "We found that too much or too little L1 expression caused development to come to a halt" explains Dr. Joanna Jachowicz (IES), first author of the paper. "This means that the precise timing and level of retrotransposon expression is critical for the development of the embryo."

Unexpectedly, the scientists showed that the mechanism behind this regulation was independent of the coding nature of the transcript and of retrotransposition, that is, the ability of these elements to 'jump' to other parts of the genome. The researchers instead turned their attention to the chromatin. Using their engineering approach, the researchers showed that expressing L1 caused chromatin to be more open, while stopping L1 expression caused chromatin to be more tightly packed.

"These results identify a novel role for retrotransposons in shaping the chromatin 'landscape' necessary for the early developmental programme", explains Torres-Padilla. "It was previously assumed that the activation of retrotransposons was simply a side-effect of the chromatin remodelling occurring after fertilisation, a process termed epigenetic reprogramming. Our study demonstrates that L1 elements have a specific role in regulating chromatin accessibility which in turn is necessary for the correct developmental programme to take place. This study is hugely significant in assigning a role to a large amount of the mammalian genome at the very earliest stages of life."

In the future, the scientists would like to explore this process further and investigate whether other transposable elements have similar functions. "The overall aim of our research is to understand the processes occurring in the early embryo" adds Torres-Padilla. "This is a very fascinating stage of development because all the cell types of the body will arise from the single cell present after fertilisation". This is particularly relevant for the field of regenerative medicine, which aims to create different cell types and organs in the petri-dish for therapeutic use.

Explore further: From pluripotency to totipotency

More information: "LINE-1 activation after fertilization regulates global chromatin accessibility in the early mouse embryo," Nature Genetics (2017). DOI: 10.1038/ng.3945

Journal reference: Nature Genetics

Provided by: Helmholtz Zentrum Mnchen - German Research Center for Environmental Health

Read this article:
Repetitive elements shape embryonic chromatin landscape - Phys.Org

Anatomy of a Goal: Ola Kamara finishes the transition – Massive Report

Welcome to the Anatomy of a Goal, where each week we dissect one goal (or near goal) from Columbus Crew SCs previous match.

For match 28 of the 2017 MLS Season, we take a look at Ola Kamaras 50th minute goal that put Crew SC up 1-0 as part of the 2-1 win over FC Dallas on Saturday.

Heres a look at the finish from the Columbus striker.

The Black & Gold returned to the teams typical 4-2-3-1 against Dallas after a successful run with that formation during a midweek match with LA Galaxy. For the first half of the game, Crew SC saw more of the ball than the Hoops but were ultimately unable to put that ball into the back of the net.

This Columbus goal was an excellent example of the Gregg Berhalter system taking the team from one end of the field to the other. The goal begins with a short goal kick played from Zack Steffen to center-back Jonathan Mensah. As Jonathan is pressured by Maximiliano Urruti, he is able to find midfielder Mohammed Abu at the top of the penaty box.

With the ball at the top of the box, Abu can pass the ball forward to creative midfielder Federico Higuain, continue to carry the ball, play a square pass to Wil Trapp, drop a pass back to Jonathan, another drop to Steffen or yet another drop back to Josh Williams.

Abu decides to send the ball forward to Higuain, who is very briefly undefended.

However, Higuain senses the impending pressure from Kellyn Acosta, so he plays the ball back to Abu who has moved a few yards forward and is still unmarked.

Again, Abu provides an important link between the midfield, defense, and attack, with multiple options. He can either continue his dribble up the field, play a quick pass back to Higuain who is marked by Acosta, drop the ball back to Trapp or Williams or a pass up the field to left back Jukka Raitala.

Abu plays a pass up the field to Raitala and continues his run forward while tracked by Lamah.

With the ball at his feet, Raitala can do one of three things. He can play a pass up the sideline to Justin Meram, continue to dribble around Carlos Gruezo or a diagonal pass to Higuain.

Raitala carries the ball across midfield and then slots a pass over to Meram.

With the ball at his feet and very little space to operate, Meram can play a difficult through pass to Pedro Santos, knock a tough diagonal ball to Higuain or drop the ball back to Raitala.

Meram decides to force the ball into the area between Santos and Higuain, but Acosta is quick to pounce on the weak pass.

However, Kamara approaches the ball at the same time as Acosta. The forwards pressure causes Acosta to play a heavy touch on the ball, right into the body of Kamara.

The above video shows Kamara and Acostas battle for this ball, and the potential goal-voiding situation that resulted from this battle. As Acosta and Kamara clash, the ball pops up into the Crew SC players midsection. Both Acosta and Walker Zimmerman shout for a hand ball, but the official allows the play to continue.

Zoomed in, judge for yourself whether this was a handball. Acosta gave the referee his thoughts after the goal, but from here it looks like Kamara settles the ball with his chest/stomach and not his arm.

As with last weeks potentially offside goal, every play is reviewed by the video assistant referee. So, it appears that VAR decided that this was not a handball.

Having won the ball from Acosta, Kamara plays a quick pass over to Higuain.

At the top of the box, Higuain can continue to dribble toward the goal or play a through ball to Hector Jimenez.

Higuain could also chip a ball into the path of Kamara or Santos, but from this angle it is clear to see that both attacking players are offside.

Seeing little attacking space to move forward, Higuain plays a perfectly weighted through ball to Jimenez.

As Jimenez sprints toward Higuains pass, he must quickly decide whether to shoot or whether to cross the ball to Kamara or Santos. With Tesho Akindele bearing down, Jimenez has to play the ball with his first touch.

Jimenez approaches the ball, and squares his hips toward Kamara to play a cross on the ground toward the striker.

From the side angle, its clear that Kamara is onside right as Jimenez squares the ball.

Jimenezs pass is a half step behind Kamara, so the striker must alter his run in order to fire in a shot on goal.

Kamara contorts his body in order to get his foot behind the ball . . .

. . . and finds the back of the net.

Findings:

Excerpt from:
Anatomy of a Goal: Ola Kamara finishes the transition - Massive Report